Sanofi: Hepatitis trials

The registry lists 11 Hepatitis studies with Sanofi as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 1Phase 2 2Phase 3 5Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® VaccineCompletedNCT02117934Phase 3Results posted
• Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B VaccineCompletedNCT01005407Phase 3Results posted
• Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) PatientsCompletedNCT00985426Phase 3Results posted
• Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus VaccineCompletedNCT00511095Phase 2Results posted
• Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® VaccineCompletedNCT00435812Phase 3Results posted
• DV2-HBV-27: Observational Pregnancy RegistryActive, not recruitingNCT03664648
• Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and AdolescentsCompletedNCT02011763Phase 4
• Regulatory Post-Marketing Surveillance Study for Hepatitis A Vaccine (AVAXIM 160U)CompletedNCT01838070
• Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on HemodialysisCompletedNCT01195246Phase 3
• A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal DiseaseTerminatedNCT00498212Phase 2
• Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure PatientsCompletedNCT00426712Phase 1